Molecular TCR diagnostics can be used to identify shared clonotypes after allogeneic hematopoietic stem cell transplantation

被引:22
|
作者
O'Keefe, CL
Sobecks, RM
Wlodarski, M
Rodriguez, A
Bell, K
Kuczkowski, E
Bolwell, BJ
Maciejewski, JP
机构
[1] Cleveland Clin Fdn, Expt Hematol & Hematopoiesis Sect, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Bone Marrow Transplant Program, Cleveland, OH 44195 USA
关键词
D O I
10.1016/j.exphem.2004.07.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. In allogeneic hematopoietic stem cell (HSCT) transplantation, recovery of the T cell receptor (TCR) repertoire depends upon the composition of the graft and is modulated by peri-transplant immunosuppression, viral infections, and graft-vs-host disease (GVHD). We hypothesized that after allogeneic HSCT, molecular analysis of the TCR repertoire can be used to identify and quantitate immunodominant T cell clones that may play a role in GVHD or other clinical events. Methods. We utilized a rational strategy for the analysis of the expanded CTL clones. First, we studied the VB spectrum in a cohort of patients who had received either matched sibling or unrelated donor grafts. The CDR3 sequences of immunodominant clones were identified and clonotypic PCR and sequencing was applied to determine the level of clonotype sharing. Results. Significant expansions of VB families were observed following transplantations; 61% were oligo/monoclonal. Immunodeficiency was reflected by depletion of multiple VB families from both the CD8 and CD4 repertoires. The level of sharing varied between clonotypes, suggesting that some antigens have a more "public" spectrum while others are restricted to specific patients. Immunodominant CDR3 sequences common to allogeneic HSCT, healthy controls, and other conditions were identified. Conclusion. The clonotypes of expanded CTL clones may reflect responses to alloantigens (e.g., in correlation with clinical GVHD) or pathogens. In the future, molecular T cell diagnostics may become a powerful clinical tool in transplantation to monitor disease and to direct treatment. (C) 2004 International Society for Experimental Hematology. Published by Elsevier Inc.
引用
收藏
页码:1010 / 1022
页数:13
相关论文
共 50 条
  • [31] Cerebral toxoplasmosis after allogeneic hematopoietic stem cell transplantation
    Abdullayev, E.
    Abdullayev, E.
    Fuhrmann, S.
    Eimermacher, C.
    Glass, B.
    LEUKEMIA RESEARCH, 2018, 73 : S57 - S58
  • [32] Pleuroparenchymal fibroelastosis after allogeneic hematopoietic stem cell transplantation
    Bondeelle, Louise
    Gras, Julien
    Michonneau, David
    Houdouin, Veronique
    Hermet, Eric
    Blin, Nicolas
    Nicolini, Franck
    Michallet, Mauricette
    Dominique, Stephane
    Huynh, Anne
    Leroy, Sylvie
    Socie, Gerard
    Thabut, Gabriel
    Reynaud-Gaubert, Martine
    Tazi, Abdellatif
    Bergeron, Anne
    BONE MARROW TRANSPLANTATION, 2020, 55 (05) : 982 - 986
  • [33] Pleuroparenchymal fibroelastosis after allogeneic hematopoietic stem cell transplantation
    Louise Bondeelle
    Julien Gras
    David Michonneau
    Véronique Houdouin
    Eric Hermet
    Nicolas Blin
    Franck Nicolini
    Mauricette Michallet
    Stéphane Dominique
    Anne Huynh
    Sylvie Leroy
    Gérard Socié
    Gabriel Thabut
    Martine Reynaud-Gaubert
    Abdellatif Tazi
    Anne Bergeron
    Bone Marrow Transplantation, 2020, 55 : 982 - 986
  • [34] Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation
    Maffini, Enrico
    Festuccia, Moreno
    Brunello, Lucia
    Boccadoro, Mario
    Giaccone, Luisa
    Bruno, Benedetto
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : 388 - 397
  • [35] Subsequent malignancies after allogeneic hematopoietic stem cell transplantation
    Gunduz, Mehmet
    Ozen, Mehmet
    Sahin, Ugur
    Toprak, Selami Kocak
    Bozdag, Sinem Civriz
    Yuksel, Meltem Kurt
    Arslan, Onder
    Ozcan, Muhit
    Demirer, Taner
    Beksac, Meral
    Ilhan, Osman
    Gurman, Gunhan
    Topcuoglu, Pervin
    CLINICAL TRANSPLANTATION, 2017, 31 (07)
  • [36] Secondary Cancer after Allogeneic Hematopoietic Stem Cell Transplantation
    Tanaka, Yosuke
    Kurosawa, Saiko
    Tajima, Kinuko
    Inamoto, Yoshihiro
    Ito, Reiko
    Tanaka, Takashi
    Inoue, Yoshitaka
    Ozawa, Takayuki
    Kawajiri, Akihisa
    Onishi, Akio
    Okinaka, Keiji
    Fuji, Shigeo
    Kim, Sung-Won
    Tanosaki, Ryuji
    Yamashita, Takuya
    Fukuda, Takahiro
    BLOOD, 2015, 126 (23)
  • [37] Toxoplasmic encephalitis after allogeneic hematopoietic stem cell transplantation
    Cetinkaya, Feyza Izci
    Mumcu, Necati
    Unuvar, Gamze Kalin
    Kilic, Aysegul Ulu
    Kaynar, Leylagul
    NORTHERN CLINICS OF ISTANBUL, 2022, 9 (03) : 282 - 285
  • [38] Aspergillus Thyroiditis after Allogeneic Hematopoietic Stem Cell Transplantation
    Ataca, Pinar
    Atilla, Erden
    Saracoglu, Pelin
    Yilmaz, Gulden
    Bozdag, Sinem Civriz
    Toprak, Selami Kocak
    Yuksel, Meltem Kurt
    Ceyhan, Koray
    Topcuoglu, Pervin
    CASE REPORTS IN HEMATOLOGY, 2015, 2015
  • [39] Cataract after allogeneic hematopoietic stem cell transplantation inchildhood
    Fahnehjelm, Kristina Tear
    Tornquist, Alba Lucia
    Olsson, Monica
    Backstrom, Ingrid
    Gronlund, Marita Andersson
    Winiarski, Jacek
    ACTA PAEDIATRICA, 2016, 105 (01) : 82 - 89
  • [40] Posaconazole concentrations after allogeneic hematopoietic stem cell transplantation
    Heinz, W. J.
    Einsele, H.
    Helle-Beyersdorf, A.
    Zirkel, J.
    Grau, A.
    Schirmer, D.
    Lenker, U.
    Klinker, H.
    TRANSPLANT INFECTIOUS DISEASE, 2013, 15 (05) : 449 - 456